Recent Analysts’ Ratings Updates for Integra LifeSciences (IART)

Several brokerages have updated their recommendations and price targets on shares of Integra LifeSciences (NASDAQ: IART) in the last few weeks:

• 10/14/2024 – Integra LifeSciences had its price target lowered by analysts at Truist Financial Co. from $26.00 to $21.00. They now have a “hold” rating on the stock.
• 10/7/2024 – Integra LifeSciences had its price target lowered by analysts at Bank of America Co. from $26.00 to $18.00. They now have an “underperform” rating on the stock.
• 10/7/2024 – Integra LifeSciences was upgraded by analysts at BTIG Research from a “sell” rating to a “neutral” rating.
• 10/1/2024 – Integra LifeSciences had its price target lowered by analysts at Citigroup Inc. from $20.00 to $16.00. They now have a “sell” rating on the stock.
• 8/28/2024 – Integra LifeSciences had its price target lowered by analysts at BTIG Research from $22.00 to $20.00. They now have a “sell” rating on the stock.
• 8/22/2024 – Integra LifeSciences had its price target lowered by analysts at Citigroup Inc. from $23.00 to $20.00. They now have a “sell” rating on the stock.

Integra LifeSciences Stock Down 0.1 %

Shares of NASDAQ:IART traded down $0.01 during mid-day trading on Monday, hitting $19.22. 816,453 shares of the company traded hands, compared to its average volume of 1,112,369. The firm’s 50 day simple moving average is $19.27 and its 200 day simple moving average is $25.98. The firm has a market cap of $1.51 billion, a P/E ratio of 38.44, a PEG ratio of 0.62 and a beta of 1.09. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The firm had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same quarter in the previous year, the business posted $0.71 EPS. The firm’s revenue was up 9.7% compared to the same quarter last year. On average, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Institutional Trading of Integra LifeSciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Trust Inc. boosted its holdings in shares of Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after buying an additional 444 shares during the period. CWM LLC boosted its stake in Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares during the period. Valley National Advisers Inc. bought a new position in shares of Integra LifeSciences during the first quarter valued at approximately $63,000. Canada Pension Plan Investment Board acquired a new stake in shares of Integra LifeSciences during the 2nd quarter worth approximately $114,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock worth $136,000 after purchasing an additional 1,711 shares during the last quarter. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.